AJCP / Meeting AbstrActs and increased bleeding (secondary to thrombocytopenia). Individuals with certain MDS subtypes are at substantially higher risk of developing acute myeloid leukemia (AML), and thus identification of people with MDS and tracking of this dysplastic population overtime could hypothetically have significant ramifications for clinical course. Due to the varied causes and manifestations of MDS, diagnosis is often difficult, and primarily relies on histologic based approaches. Given the recent advancements in multiparameter flow cytometry, we determined if MDS-related changes could be detected by 10-color flow cytometry. Previous work has demonstrated that MDS is associated with loss of blast heterogeneity typically seen in the bone marrow of normal individuals. Specifically, CD34+ blasts from normal individuals exhibit a pattern with at least three cell populations based on expression of CD13 and HLA-DR, a pattern that was lost in MDS patients. Additionally, a separate report demonstrated that MDS was correlated with a significant decrease in hematogones (precursor B cells) in the bone marrow. These processes, loss of blast heterogeneity and hematogones, may correlate with one another and be directly related; however this has not been formally assessed. Here, we describe an approach evaluating MDS by examining both blast heterogeneity as well as hematogones. As was previously reported, we found that there was variable loss of blast heterogeneity in bone marrow specimens from MDS patients compared with bone marrow specimens from normal/random patients. We also found that the relative fraction of hematogones was also decreased in individuals with MDS. Further, it appeared that the relative loss of blast heterogeneity might correlate with the relative degree of hematogone loss in the bone marrow. Results were correlated with histologic findings, including assessment of the blast population by CD34 immunohistochemical staining, cytogenetic findings, and additional molecular diagnostic findings. Thus, combining these two approaches may provide additional insight into MDS and be useful as an additional diagnostic modality for the initial diagnosis and therapeutic tracking of MDS as well as other myeloid neoplasms.
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Understanding the Mechanism of Acquired von Willebrand Disease in Patients With Wilms Tumor
Ritu Gupta, Morayma Reyes-Gil; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY Acquired von Willebrand disease (vWD) has been shown to occur in patients with Wilms tumors. Possible mechanisms of acquired vWD-associated malignancy described in the literature include selective absorption of high molecular weight multimers by the malignant cells, aberrant expression of GP1b or GP IIb ⁄IIIa receptors by the tumor cells, and autoantibodies. The most common malignancies associated with acquired vWD are hematologic, such as multiple myeloma, myelodysplastic syndrome, and amyloidosis. Among solid neoplasia, Wilms tumor is the most commonly associated with acquired vWD. The most characterized mechanism in Wilms tumor is high levels of hyaluronic acid secreted by nephroblastoma cells, which increases viscosity and binds von Willebrand factor (vWF). A dated prospective study showed an 8% prevalence of acquired vWD with a multimer pattern of
